Clients News • MC Services corporate website

5522

paged,page-template-default,page,page-id-5522,paged-63,page-paged-63,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.4.2,vc_responsive

CLIENT NEWS

Allergy Therapeutics announces business development ppdate and publication date of half year results for FY 2018/2019
16 January 2019
www.allergytherapeutics.com
Newron Pharmaceuticals: Commercialization partner Zambon together with Valeo Pharma announce the approval of Onstryv® (safinamide) for Parkinson’s disease in Canada
16 January 2019
www.newron.com
Adocia confirms its financial calendar for 2019
16 January 2019
www.adocia.com
Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance
14 January 2019
www.veronapharma.com
Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554
10 January 2019
www.veronapharma.com
HPS Home Power Solutions GmbH begins delivery of the first Picea customer systems
09 January 2019
www.homepowersolutions.de
Medigene AG: Additional European patent granted for Medigene’s DC vaccine platform
08 January 2019
www.medigene.com
Expedeon AG licenses Lightning-Link® Rapid Biotinylation technology to Cell Guidance Systems in supply agreement
08 January 2019
www.expedeon.com
Sterna biologicals prepares for phase IIb clinical program with GATA-3 antagonist drug candidates SB010 in asthma and SB012 in ulcerative colitis
08 January 2019
www.sterna-biologicals.com
AYOXXA signs research agreement in the field of ophthalmology with one of the leading pharmaceutical companies
08 January 2019
www.ayoxxa.com